Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc Narrows FY 2013 EPS Guidance To A Range Above Analysts' Estimates; Reaffirms FY 2013 Revenue Guidance


Monday, 28 Oct 2013 07:00am EDT 

Merck & Co Inc announced that for fiscal 2013, it expects non-GAAP earnings per share (EPS) to be between $3.48 and $3.52, and the 2013 GAAP EPS to be between $1.61 and $1.79. The fiscal 2013 non-GAAP range excludes acquisition-related costs, costs related to restructuring programs and certain other items. At current exchange rates, Merck continues to anticipate fiscal 2013 sales to be approximately 5% to 6% below prior year levels with foreign exchange accounting for approximately 2.5 percentage points of the decline. The Company reported revenue of $47.267 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $3.47 for fiscal 2013. 

Company Quote

59.58
0.6 +1.02%
19 Dec 2014